Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 16/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321623 | 0.88 | IDO1 (0.54) | IDO1MAOB | |
| SCHEMBL9033990 | 0.85 | GPR84 (0.45) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL5146701 | 0.80 | IDO1 (0.45) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL5672700 | 0.79 | IDO1 (0.41) | IDO1MAOB | |
| SCHEMBL9034118 | 0.77 | GPR84 (0.39) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL9036408 | 0.77 | IDO1 (0.45) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL9038883 | 0.77 | TAAR1 (0.49) | IDO1MAOB | |
| SCHEMBL697657 | 0.77 | FFAR1 (0.40) | IDO1MAOBSLC6A4 | |
| SCHEMBL95381 | 0.76 | TSHR (0.44) | IDO1MAOB | |
| SCHEMBL10830875 | 0.76 | TACR1 (0.41) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | disclosed |
| US-20210100773-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2021-04-08 | — | — | US | disclosed |
| US-10729677-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-I | EUSTRALIS PHARMACEUTICAL LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-08-04 | — | — | US | disclosed |
| US-20160143881-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACETICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2016-05-26 | — | — | US | disclosed |
| EP-2104494-A1 | METHOD FOR REDUCING INFLAMMATORY RESPONSES AND INFLAMMATION | Adelaide Research & Innovation Pty Ltd. (AU) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008067610-A1 | METHOD FOR REDUCING INFLAMMATORY RESPONSES AND INFLAMMATION | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2008-06-12 | — | — | WO | disclosed |
| US-5561130-A | USED TO PREVENT OR TREAT PAIN, INFLAMMATION, MIGRANES AND/OR ARTHRITIS | MERCK SHARP & DOHME LIMITED (GB) | 1996-10-01 | — | — | US | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |